Business Wire

SV Life Sciences Managers LLP, Manager of Dementia Discovery Fund (DDF) Appoints World-Renowned Chief Scientific Officer to Lead the New DDF Investment Team

25.1.2016 07:00 | Business Wire

Del

The Dementia Discovery Fund (DDF) www.TheDDFund.com, an innovative global investment fund launched in October 2015 to discover and develop new disease modifying drugs for dementia, announces the appointment of Tetsuyuki Maruyama PhD as its Chief Scientific Officer.

Dr Tetsuyuki Maruyama will join the DDF in April 2016 from Takeda Pharmaceutical Co. Ltd where for the past five years he has been Senior VP, General Manager, Pharmaceutical Research Division, leading global drug discovery after his initial appointment as Head of CNS Research. Prior to this he was Director of GlaxoSmithKline Plc’s neuroscience research centre in Singapore, and led Alzheimer’s Disease target discovery efforts at Merck Sharpe & Dohme, Ltd. Dr Maruyama has lectured in neuroscience at Yale University, the University of Minnesota, the University of Edinburgh, and Cardiff University, where he was Professor in the Cardiff School of Biosciences. Dr Maruyama’s research has been published in the world’s leading scientific journals (under his previous name, Paul Chapman).

In addition, Dr Laurence Barker will join the DDF as Chief Business Officer in February 2016 from GlaxoSmithKline Plc where he has been Head of Investment Management, Worldwide Business Development. He has previously held business development roles at Syntaxin Ltd and MorphoSys AG and has an MBA from the University of Cambridge.

Barbara Tate joined the DDF as Venture Partner in Boston following the successful $485m deal between Biogen and Rodin – which she helped start with Atlas Venture. Dr Tate was previously Senior Director of Neuroscience at Pfizer following her long successful academic career at Harvard and Brown.

Dr Maruyama, Dr Barker, Dr Tate all join Dr Carol Routledge who joined the DDF in September 2015. Dr Routledge was previously Head of Translational Medicine, Biopharm Discovery, GSK, following 30 years of neuroscience drug discovery and development experience from prior roles at GSK, Syntex, Wyeth and BTG.

Kate Bingham, Managing Partner at SV Life Sciences Managers LLP, manager of the DDF, said: “The assembly of such a high calibre DDF team so soon after the Fund’s launch demonstrates the interest in this field and belief in what this Fund can deliver. Tetsu’s experience in global discovery, both in big pharma and academia, is exceptional and we look forward to welcoming him and Laurence soon.”

Tetsuyuki Maruyama, Chief Scientific Officer of the DDF, added: “The DDF has the mission to change the approach, diagnosis and treatment of dementia and I am pleased to be joining such a strong team who have already made significant progress since launch towards this ambitious goal.”

For further information please visit the DDF website at www.theddfund.com

About the Dementia Discovery Fund

The DDF is an innovative global investment fund established in October 2015 to deliver new disease modifying drugs for dementia by 2025. Managed by SV Life Sciences Managers LLP, DDF investors include the UK Government’s Department of Health, Alzheimer’s Research UK and world-leading major pharmaceutical companies: Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda. The DDF works collaboratively with universities, academic institutes, government, the regulatory agencies and the biotechnology and pharmaceutical industry internationally to identify and develop novel dementia research projects.

About SV Life Sciences Managers LLP

SV Life Sciences Managers manages life sciences investments for both the Dementia Discovery Fund (www.TheDDFund.com) and the publicly listed fund International Biotechnology Trust plc (www.ibtplc.com). The investment team have a breadth of experience across both public and private investing.

THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION. NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES.

Contact information

Dementia Discovery Fund
Carol Routledge, +44 20 7421 7091
Venture Partner
carol.routledge@svlsm.com
or
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Amber Fennell, Ivar Milligan
+44 20 3709 5700
DDF@consilium-comms.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04Pressemelding

Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We

Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57Pressemelding

Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio

Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08Pressemelding

On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00Pressemelding

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia

Smarsh Adds Voice Archiving Offering with Acquisition of London-Based Cognia17.8.2017 06:59Pressemelding

Smarsh®, providing information archiving solutions for compliance, e-discovery and risk management, has completed the acquisition of Cognia, a worldwide leader in cloud-based voice archiving, audio search and analytics. Smarsh will leverage Cognia’s intellectual property and development resources to offer its global customer base enhanced capabilities around mobile and fixed-line voice communication – alongside a market-leading range of electronic communications – within The Archiving Platform. The acquisition will expand the existing presence of Smarsh in Europe and is central to its MiFID II compliance solution for financial firms. In addition to capturing incoming and outgoing communication from fixed-line recording solutions, Cognia uniquely captures voice content directly from leading mobile carriers. Carrier-direct capture is the most reliable and automated method for capt

Schlumberger Announces Third-Quarter 2017 Results Conference Call16.8.2017 21:23Pressemelding

Schlumberger Limited (NYSE:SLB) will hold a conference call on October 20, 2017 to discuss the results for the third quarter ending September 30, 2017. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call,

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom